OPTICAL VISION LIMITED

Company number 03323205 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: OPTICAL VISION LIMITED

1. Financial Health Score: B+

Explanation: The patient exhibits robust constitution with exceptional cash reserves and minimal external debt, but is showing concerning symptoms of declining operational vitality. The 44% drop in profitability, combined with a dividend payout exceeding earnings, suggests the business may be entering a mature phase where cash generation is prioritised over growth. The heavy reliance on intercompany funding and declining trading indicators warrant monitoring.


2. Key Vital Signs

💓 Liquidity Pulse – Exceptionally Strong (98/100)

Metric 2024 2023 Interpretation
Current Ratio 2.96x 2.96x Excellent – well above the 1.5x healthy threshold
Quick Ratio 2.30x 2.19x Outstanding – can cover liabilities without selling stock
Cash Ratio 2.11x 1.78x Exceptional – cash alone covers liabilities twice over

Reading: The patient's circulatory system is flooded with liquidity. With £7.44M in cash against £3.53M in current liabilities, the company could pay all its debts tomorrow and still have over £3.9M remaining. This is financial hydration at its finest.


🫀 Balance Sheet Heart – Strong but Changing (82/100)

Metric 2024 2023 Change
Net Assets £6,914,378 £7,050,591 -1.9%
Net Current Assets £6,908,483 £7,043,641 -1.9%
Shareholders' Funds £6,914,378 £7,050,591 -1.9%
Fixed Assets £5,895 £6,950 -15.1%

Reading: The heart remains powerful, but there's a slight weakening. Net assets have declined modestly, and fixed assets are negligible at under £6,000 – suggesting the company operates an asset-light model or has minimal capital investment requirements. The equity base of nearly £7M on just £50,000 of share capital shows a business that has grown substantially through retained profits.


🧠 Profitability Brain – Declining Function (55/100)

Metric 2024 2023 Change
Profit for Year £363,787 £652,870 -44.3%
Return on Equity 5.3% 9.3% -4.0pp
Dividend Payout £500,000 £500,000 Flat
Payout Ratio 137.4% 76.6% +60.8pp

Reading: This is the most concerning vital sign. Profitability has suffered a significant decline – down 44% year-on-year. More worryingly, the dividend of £500,000 exceeds the profit of £363,787, meaning the company is distributing £136,213 more than it earned. This is akin to a patient burning more calories than they're consuming – sustainable for a short period given the fat reserves (accumulated profits), but not viable long-term.


🫁 Cash Flow Lungs – Deep Breathing (90/100)

Year Cash Position Year-on-Year Change
2024 £7,439,949 +£1,035,127 (+16.2%)
2023 £6,404,822 +£173,247 (+2.8%)
2022 £6,231,575 +£1,836,836 (+41.8%)
2021 £4,394,739 -£2,037,030 (-31.7%)
2020 £6,431,769 +£3,363,651 (+109.6%)

Reading: Cash reserves continue to swell, reaching their highest level in the recorded history. The lungs are functioning well, but the increased cash may partly result from reduced inventory purchasing and lower capital investment rather than purely operational cash generation.


🔬 Debt & Leverage Blood Pressure – Healthy (88/100)

Metric 2024 Analysis
Total Liabilities £3,529,832 Well-covered by assets
Debt-to-Equity Ratio 0.51x Healthy – below 1.0x threshold
Third-Party Debt Ratio 0.08x Exceptionally low excluding intercompany
Intercompany Debt £2,948,368 83.6% of total liabilities
Trade Creditors £85,168 Minimal supplier leverage

Reading: Blood pressure is well within healthy limits. The majority of debt (83.6%) is owed to group undertakings – this is intercompany debt within the Goldfyre Limited group structure, not third-party obligations. Stripping this out, external liabilities are only £581,464, giving a true third-party debt-to-equity ratio of just 0.08x. The patient is not over-leveraged by any clinical measure.


📊 Trading Activity Muscles – Weakening (50/100)

Metric 2024 2023 Change
Stocks £2,331,080 £3,335,542 -30.1%
Trade Debtors £539,265 £432,926 +24.5%
Employee Count 14 15 -1
Other Debtors £21,051 £15,615 +34.9%

Reading: The 30% decline in inventory is striking. While this could indicate improved stock management, combined with falling profits and reduced headcount, it more likely signals reduced business activity. Trade debtors have increased by 24.5%, which could indicate slower payment collection or extended credit terms to maintain sales volumes.


3. Diagnosis

Primary Diagnosis: Mature Cash-Rich Business with Declining Operational Vitality

The patient presents as a financially secure but operationally contracting entity. The core diagnosis reveals several interconnected conditions:

1. Asset-Light, Cash-Heavy Constitution The company holds 71.3% of its assets in cash (£7.44M of £10.44M total assets). This is an unusually high concentration that suggests either: - The business operates as a cash repository within the Goldfyre Limited group structure - Management is conserving cash due to uncertain market conditions - There's a lack of viable investment opportunities

2. Intercompany Dependency Syndrome With £2.95M owed to group undertakings (representing 83.6% of total liabilities), this company is financially intertwined with its parent. This is common in group structures but means the company's financial health is partially dependent on the broader group's strategy and stability.

3. Profitability Deterioration The 44% decline in profit is the most acute symptom. While still profitable, the trajectory is concerning. The reduction from £652,870 to £363,787 represents a significant contraction in earning power.

4. Unsustainable Dividend Policy Distributing £500,000 when earning only £363,787 means the company is eating into its reserves. Over time, this erodes the equity base unless profitability recovers.

5. Inventory Contraction The 30% drop in stocks from £3.34M to £2.33M, combined with rising trade debtors, may indicate the company is winding down certain product lines or experiencing reduced demand.


4. Recommendations

Immediate Treatment (0-6 months)

1. Review Dividend Policy 🔴 Urgent The current payout ratio of 137% is unsustainable. Recommend reducing dividends to align with actual profitability (maximum £350,000 based on current earnings) or establishing a clear policy linking dividends to a sustainable percentage of profits (e.g., 60-70% payout ratio).

2. Profitability Investigation 🔴 Urgent Conduct a detailed analysis of the profit decline: - Is it revenue-driven (lower sales volumes/prices)? - Is it margin-driven (increased cost of sales)? - Is it expense-driven (overhead increases)? - Are there one-off factors distorting the comparison?

3. Cash Deployment Strategy 🟡 Important With £7.44M in cash earning minimal returns, consider: - Repaying intercompany debt to reduce group leverage - Investing in business growth initiatives - Evaluating whether some cash should be redistributed upstream to the parent company for group-level deployment

Medium-Term Treatment (6-18 months)

4. Working Capital Optimisation 🟡 Important - Investigate the 24.5% increase in trade debtors – are customers paying slower? - Review whether the inventory reduction is strategic or symptomatic of declining demand - Consider whether the stock level of £2.33M is optimal for current trading

5. Strategic Direction Review 🟢 Advisory Given the company's status as a subsidiary within the Goldfyre group, clarify: - What is the strategic purpose of this entity within the group? - Is it intended to grow, maintain, or wind down? - Should the cash be redeployed elsewhere in the group?

6. Investment Appraisal 🟢 Advisory With only £5,895 in fixed assets and 14 employees, the business appears to operate an extremely lean model. If growth is desired, evaluate: - Capital investment opportunities - Market expansion potential - Digital/technology investments

Long-Term Health Maintenance

7. Group Structure Efficiency 🟢 Advisory Review the intercompany funding structure with Goldfyre Limited to ensure it's tax-efficient and aligned with group strategy.

8. Performance Benchmarking 🟢 Advisory Establish KPIs and regular monitoring to track: - Gross and net profit margins - Revenue trends (not visible in filed data due to small company exemptions) - Stock turnover ratios - Debtor days


Risk Factors to Monitor

Risk Likelihood Impact Mitigation
Continued profit decline Medium High Cost review, revenue diversification
Cash erosion from excessive dividends Medium Medium Align dividends to earnings
Intercompany dependency Low Medium Clear group funding agreements
Inventory obsolescence Low Medium Regular stock reviews
Customer concentration Unknown High Diversify customer base

Historical Trend Analysis

The five-year trajectory shows a business that grew significantly from 2018-2020, with shareholders' funds nearly doubling from £3.77M to £4.73M (2018-2020), then accelerating to £6.19M (2021), £6.90M (2022), and peaking at £7.05M (2023). The slight decline to £6.91M in 2024 represents the first contraction in the recorded period, driven by the dividend exceeding profits.


Perspective: Financial Health Diagnostician · Model: glm-5.1 · Generated 21 September 2026